225 results about "Diagnostic agent" patented technology

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

The invention provides an intelligent equipment operation and maintenance method and system based on an industry large model technology, equipment and a medium, and belongs to the technical field of intelligent equipment operation and maintenance. Inputting the equipment operation data into a multi-agent cooperation engine, and analyzing time domain, frequency domain and working condition parameters; the diagnosis agent generates diagnosis result information in combination with the diagnosis intelligent knowledge graph; the diagnosis result information is converted into a work order text, and the work order text is synchronized to a monitoring system; after fault processing is completed, the processing process and result are fed back to the monitoring system and supplemented to the diagnosis intelligent knowledge graph based on a supplement mechanism, and knowledge iteration updating is achieved. A multi-dimensional data fusion and analysis method is adopted. Information of different types of data is utilized, and the accuracy and reliability of fault diagnosis and operation and maintenance decision are improved through a multi-dimensional analysis perspective.

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

The present invention pertains to the field of medical devices and introduces an enteral tube system designed for efficient and continuous delivery of fluids into a patient's gastrointestinal tract. The system integrates a one-way air valve along the tubular body, allowing ambient air to equalize negative pressure within the tube. This innovative feature enables the plunger of a syringe connected to the syringe port to be removed and the syringe refilled without disconnecting it, ensuring uninterrupted operation. The system also includes an enteral connector with user-controlled fluid flow pathways, enhancing versatility and precision during fluid administration. By addressing challenges such as negative pressure buildup and simplifying the refilling process, the invention reduces handling complexity and improves overall efficiency. The system is suitable for administering enteral fluids, medications, or diagnostic agents in healthcare settings, offering significant advantages over traditional enteral feeding systems.

The invention discloses an ultrasonic molecular probe. The ultrasonic molecular probe comprises a targeted contrast agent and siRNA of fibronectin, wherein the targeted contrast agent and the siRNA are connected through G0-C14; the targeted contrast agent comprises gas vesicles covalently linked with annular polypeptide, and the annular polypeptide targets an atherosclerotic plaque region. The cyclic polypeptide can be combined with the outer structural domain B of fibronectin with high specificity, and the atherosclerotic plaque extracellular matrix is rich in the outer structural domain B of the fibronectin, so that enough targeted ultrasonic contrast agent can be quickly combined in the plaque region to generate strong signal enhancement in ultrasonic imaging, and on the basis, the targeted ultrasonic contrast agent can be quickly combined with the plaque region to generate strong signal enhancement in ultrasonic imaging. The ultrasonic molecular probe releases siRNA for atherosclerotic plaque treatment, and atherosclerotic plaque diagnosis and treatment integration is achieved. The invention further discloses a preparation method of the ultrasonic molecular probe and application of the ultrasonic molecular probe in preparation of atherosclerotic plaque diagnostic agents, drugs and drug delivery agents.

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

The invention discloses preparation and application of a novel diagnostic kit for a mitochondrial network regeneration function evaluation test, and in the invention, combined detection of related proteins DRP1, MFN2, OPA1 and TIM23 is carried out by utilizing four mitochondrial networks, so that the mitochondrial regeneration function state of sample cells is judged. The kit disclosed by the invention is used for detecting samples such as human blood, urine, cell cultures and tissues by utilizing an ELISA (Enzyme-Linked Immunosorbent Assay) method. Results show that the kit can accurately detect the content of four proteins so as to judge the function of sample mitochondria. The mitochondrial network regeneration capacity function evaluation kit based on a double-antibody sandwich method in an ELISA method can conveniently and accurately evaluate the mitochondrial network regeneration capacity in a human body specimen. The invention discloses preparation and application of the novel diagnostic kit for evaluating the regeneration function of the mitochondrial network. The diagnostic kit plays an auxiliary role in mitochondrial detection in scientific research and disease diagnosis and treatment. The method is applied to mitochondrial function evaluation in all diseases with abnormal cell mitochondrial functions.

Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA / FTY720 / PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.

Compositions comprising microalgal extracellular vesicles (MEVs) formulated for intranasal delivery are provided, whereby upon intranasal administration, the MEVs are transported by a specific route, to specific regions in the brain via the olfactory nerve after intranasal administration, and to interconnected brain regions through the lateral olfactory tract (LOT). The MEVs are transported via neuronal axonal transport. The MEVs have the ability to cross synapses including: (i) synapses between olfactory sensory neurons (OSNs) and mitral / tufted neurons; (ii) synapses between mitral / tufted neurons and local neurons in multiple brain regions colonized by the lateral olfactory tract (LOT); and (iii) synapses between neurons in brain regions colonized by the LOT and neurons from the frontal cortex, hippocampus, thalamus, and hypothalamus. The compositions contain extracellular vesicles (MEVs) from microalgae loaded with bioactive cargo for the treatment, detection, diagnosis, or monitoring of diseases, disorders, or conditions of or involving the brain, particularly neuronal delivery of the cargo. The compositions and methods have multiple applications as therapeutic and diagnostic agents for the treatment, diagnosis, and monitoring of diseases, disorders, or conditions of or involving the brain. The compositions can be used in methods and uses for the treatment of cancers involving the brain, and can be used, for example, to deliver therapeutic agents for psychiatric diseases, disorders, conditions, and to deliver therapeutic agents for neurodegenerative diseases, disorders, and conditions.

The invention relates to the technical field of neutron dose and internal pollution diagnosis, and provides a neutron dose and internal pollution diagnosis method and diagnostic agent.The method comprises the following steps that gamma ray signals are obtained at the head top and the lung of a human body through a detection device, and gamma rays are converted into electric pulse signals through the detection device; a digital multi-channel signal processing device is used for conducting signal processing on the electric pulse signals, signal processing comprises digital filtering and peak value sampling, and energy spectrum data are obtained; analyzing the energy spectrum data, and respectively obtaining a Na-24 characteristic gamma photon peak value at the top of the head of the human body and a characteristic gamma photon peak value at the lung of the human body; and according to the Na-24 characteristic gamma photon peak value obtained at the top of the head, calculating the neutron exposure dose according to a neutron dose algorithm, and according to the characteristic gamma photon peak value obtained at the lung, determining the type and activity of the internal pollution nuclide. According to the invention, accurate calculation of neutron dose and identification and activity determination of internal pollution nuclide are realized, and dual functions of neutron exposure dose and internal pollution diagnosis can be provided at the same time.

This disclosure relates to polyethylene glycol (PEG)-functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.

The present invention relates to a supramolecular self-assembly system, comprising the following ingredients:(2) one or more carriers (or building blocks), which are water-soluble or at least soluble under pH≤8 conditions, where at least one carrier is amphiphilic with a hydrophobic group and a hydrophilic group; and(3) one or more targets, preferably the targets are active ingredients such as drugs, diagnostic agents, biomarkers, vaccines, nutrients, or cosmetic active ingredients, and preferably in a free, salt, hydrate, or solvate form.

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The present disclosure regards PSMA targeting urea-based ligands comprising a PSMA targeting moiety, a linker, and a pyridazine moiety. The PSMA targeting urea-based ligands disclosed are suitable for use as radiopharmaceuticals, either as imaging agents, such as diagnostic agents, or for the treatment of prostate cancer or as theranostic agents.

The invention discloses a community old-age care facility planning diagnosis and feedback method based on multiple agents. The method comprises five main steps of constructing a target community spatio-temporal data integration platform, constructing a target community elderly intelligent agent model, constructing a community old-age care facility planning scheme diagnosis intelligent agent, diagnosing a target community old-age care facility layout scheme, and performing decision feedback on the target community old-age care facility layout scheme. The invention aims to accurately analyze differentiated space-time behaviors of the old people in the community and excavate rules by applying a crowd digital portrait technology, and construct an old people intelligent agent in a target community; and determining key index composition of community pension facility planning scheme diagnosis and constructing a diagnosis agent, so that scheme diagnosis of facility layout can be performed and optimization decision feedback can be performed in combination with a real community physical environment and a pension facility planning scheme. According to the invention, layout diagnosis and optimization suggestion output of the target community old-age care facility planning scheme can be realized.

Disclosed herein are devices and methods for isolation and analysis of exosomal molecules from cell DNA samples. Such devices and methods facilitate isolation of ecDNA for downstream applications, such as cellular analysis and design of probes or therapeutic agents, in order to detect or target ecDNA for degradation or cells carrying ecDNA. Similarly, disclosed herein are compositions enriched for ecDNA and their use in the development of therapeutic or diagnostic agents.

A diagnostic agent for pancreatic cancer, the diagnostic agent comprising: a primer set for amplifying SLC12A7 DNA or mRNA in a sample derived from a subject; and / or a probe that binds to the SLC12A7 DNA, mRNA or an amplification product thereof, or an antibody that binds to SLC12A7 protein. An anti-pancreatic cancer agent comprising an SLC12A7 inhibitor as an active ingredient.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

The present invention relates to agents and methods for targeted delivery of a payload to a cell. The payload comprises various molecules, such as therapeutic or diagnostic agents, in particular toxins, immunomodulators or radiodiagnostic agents. In some embodiments, the invention relates to providing a subject with a compound comprising a payload moiety and at least two tags (tag conjugates) and a compound (docking compound) that binds to the tags of the tag conjugates and a target antigen (e.g., a cell surface antigen on a target cell).

The invention relates to the technical field of vehicle diagnosis, and discloses a multi-core chip, a vehicle diagnosis method and a vehicle diagnostic agent.The multi-core chip comprises a first kernel, a second kernel and a third kernel, the first kernel is used for establishing encrypted communication connection with a mobile terminal, and the second kernel is used for establishing encrypted communication connection with the mobile terminal; receiving a configuration data packet required by vehicle diagnosis from the mobile terminal; the second kernel is used for sending a diagnosis instruction to the vehicle-mounted control unit based on the configuration data packet, collecting diagnosis data as diagnosed information, and returning the diagnosed information to the mobile terminal through the first kernel; and the third kernel is used for establishing a bidirectional encryption channel between the first kernel and the second kernel by using the first communication key distributed to the first kernel and the second communication key distributed to the second kernel. The safety, the integration level and the communication efficiency of the vehicle diagnosis system are remarkably improved.

The invention discloses a nano diagnosis and treatment agent capable of monitoring the AS disease course. The diagnosis and treatment agent is prepared from phospholipid, auxiliary lipid, antioxidant nano enzyme, a fluorescent probe compound, a loaded drug and an LDL adsorption functional polymer. According to the AS nano diagnosis and treatment agent, efficient endothelial barrier penetration is achieved by taking LDL, a traditional passive penetration mode depending on the ELVIS effect is broken through, and the plaque penetration efficiency of a fluorescent probe and a treatment medicine is improved; a disease course-related plaque specific imaging system is constructed by taking the migration rate of LDL to the interior and subcutaneous tissues as a dynamic indication, and accurate monitoring of the AS development stage is realized; the antioxidant nano-enzyme with mimic enzyme activity is adopted as a core, active oxygen is removed, oxidation of a key pathogenic factor LDL is inhibited, and the function of slowing down AS progress is achieved. The invention provides a new strategy for realizing the integration of disease course monitoring and diagnosis and treatment of the AS.

The application relates to the field of biomedical technology, and discloses a diagnostic agent for identifying melanoma molecular subtype typing and application, wherein the diagnostic agent comprises a first antibody specifically combined with a SOX10 protein and a second antibody specifically combined with an EGR1 protein; the diagnostic agent can be applied to preparation of a diagnostic product for evaluating the prognostic effect of a melanoma patient, preparation of a diagnostic product for predicting the treatment sensitivity of melanoma to a BRAF inhibitor, and preparation of a diagnostic product for guiding an individualized treatment scheme of melanoma. The diagnostic agent for melanoma molecular subtype typing can be directly transformed into clinical practice, and can assist in realizing real individualized treatment.

The present invention relates to a bispecific anti-tumor antigen / anti-HSG antibody having screened light and heavy chain variable domains, which is capable of improving the pre-targeting of tumors for the specific delivery of therapeutic or diagnostic agents. The antibodies have a significant affinity for tumor antigens and stay at desired sites for a sufficient time. Antibodies that do not bind to the antigen can be rapidly cleared from the body, minimizing exposure of normal tissue. A humanized anti-HSG antibody is bound to each of a group containing histamine-succinyl-glycine (HSG) and a tumor antigen with high affinity. The bispecific antibodies can be further Fc silenced, resulting in additional properties, such as reduced binding to Fc [gamma] R and FcRn, thereby modulating effector function and regulating half-life. These antibodies are useful in the diagnosis and treatment of subjects suffering from malignancies.

A compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein W is oxygen or sulfur; X1 is -L1-R1; Y1 is -L1-R2; Z1 is L2-R3-L1-R4; L1 is independently a bond or a linking group at each occurrence; L2 is O, S or NH; R3 is optionally substituted arylene, heteroarylene, cycloalkylene or heterocyclylene; one of R1, R2 and R4 is a targeting group, and the remaining two are independently a targeting group, a drug molecule group, an isotope chelating agent or a labeling precursor group, a fluorescent or molecular tag group or a capping group. Further provided in the present disclosure are a chelate, a pharmaceutical composition and the use thereof as diagnostic agents or therapeutic agents for the diagnosis and treatment of diseases.

The embodiment of the present invention relates to the field of computer technology, and discloses a program-initiated diagnostic method, device, equipment, and readable storage medium, the method comprising: obtaining an application program inserted with a diagnostic agent program, the diagnostic agent program including a connection package and an expansion plug-in package; starting the application program inserted with the diagnostic agent program, and at the same time using the diagnostic agent program and the class loader of the application program to isolate the operating environment of the diagnostic agent program and the application program, and using the connection package to establish a call chain between the diagnostic agent program and the application program to perform function calls between the application program and the diagnostic agent program; based on the connection package, the expansion plug-in package and the class loader, the application program is monitored to obtain the diagnostic result data of the application program. The application of the technical solution of the present invention can improve the accuracy and flexibility of the program-initiated diagnosis.

An aromatic compound is composed of a stable isotope, in which two adjacent carbon atoms are 13C, atomic nuclei of other atoms to which the two adjacent carbon atoms are bonded have a spin quantum number of 0, and a hydrogen atom which has a spin coupling constant and is bonded to the 13C nucleus through a carbon atom is substituted with a deuterium atom. In the aromatic compound, a relaxation time of a 13C nucleus excited by a DNP device is longer than that in the related art.

The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof.

A major obstacle in the field of biotherapeutics is the need for platform technologies that enable high bioavailability and long-term therapeutic exposure of biotherapies in localized disease. Traditional approaches result in problematic trade-offs, such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST), which can bind to biological structures, such as the extracellular matrix, via heparan sulfate without the undesired neutralizing effects on the activity of activin A, myostatin, and GDF11, as full-length follistatin does. The present invention relates to fusion or conjugated proteins, compositions thereof, constructs or vectors encoding them, their medical uses, and methods for biotherapeutics.

Nanoconstructs consisting of a core and a lipid coating, suitable for conveying therapeutic and diagnostic (or "theranostic") agents to target tissues or organs, delivering them to the cells of interest where the nanoparticle load is released, are described. A further aspect of the invention concerns diagnostic, therapeutic or theranostic compositions comprising coated nanoparticles together with pharmaceutically acceptable vehicles or excipients.